Renaissance Technologies LLC Sells 21,900 Shares of Moderna, Inc. (NASDAQ:MRNA)

Renaissance Technologies LLC decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 20.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 85,900 shares of the company’s stock after selling 21,900 shares during the period. Renaissance Technologies LLC’s holdings in Moderna were worth $10,201,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after buying an additional 6,248,623 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Moderna by 42.9% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after purchasing an additional 463,960 shares during the period. Matrix Capital Management Company LP purchased a new stake in shares of Moderna during the 4th quarter valued at approximately $45,150,000. Finally, Nikko Asset Management Americas Inc. lifted its stake in shares of Moderna by 156.9% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after buying an additional 453,004 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 over the last three months. Insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRNA. Evercore ISI reissued an “in-line” rating and set a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. Leerink Partners decreased their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Piper Sandler lowered their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Finally, Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and an average target price of $100.44.

Moderna Price Performance

Shares of Moderna stock opened at $64.14 on Tuesday. The business’s 50-day moving average price is $88.92 and its 200-day moving average price is $110.71. The firm has a market capitalization of $24.58 billion, a PE ratio of -4.09 and a beta of 1.67. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period last year, the firm posted ($3.62) earnings per share. The business’s revenue was down 29.9% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.